Metformin in Safety and Efficacy in Gouty Patients

ConditionGout
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-60
SponsorMostafa Bahaa

About this trial

The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients

Eligibility criteria

Qualifiers

Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology/European League Against Rheumatism criteria of gout.

Disqualifiers

Systemic disorders such as cardiovascular, neurological, coronary artery disease.

Hypertension, hyperlipidemia, diabetes mellitus, active infections.

Other inflammatory or autoimmune diseases.

Patients on biologics,

Trial design

Treatments tested in this trial

  • placebo
  • Metformin

Treatment groups

70 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Mostafa Bahaa

Lead sponsor

Tanta University

Sponsor institution